145213-48-5

Basic information

• Product Name: 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
• Synonyms: 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine;2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, rel-;2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-;2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, cis-(+-)-;2',3',5-Ftc;3'-Thia-2'.3'-dideoxy-5-fluorocytidine;5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
• CAS NO: 145213-48-5
• Molecular Formula: C8H10FN3O3S
• Molecular Weight: 0
• Mol File: 145213-48-5.mol
• Article Data: 35

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one(145213-48-5)
• EPA Substance Registry System: 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one(145213-48-5)

Safety Data

• Hazardous Substances Data: 145213-48-5(Hazardous Substances Data)

Upstream product

• 1313482-37-9 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one monosuccinate 
• 144371-00-6 (+/-)-cis-2',3'-dideoxy-5-fluoro-3'-thiacytidine 
• 149819-36-3 (+)-(2S,5R)-5-fluoro-1-<2-<<(tert-butyldiphenylsilyl)oxy>methyl>-1,3-oxathiolan-5-yl>-N₄-benzoylcytosine 
• 144371-00-6 trans-2-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane 
• 149819-37-4 (-)-(2S,5S)-5-fluoro-1-<2-<<(tert-butyldiphenylsilyl)oxy>methyl>-1,3-oxathiolan-5-yl>-N₄-benzoylcytosine 
• 145986-20-5 (+)-(2R,5R)-5-fluoro-1-<2-<<(tert-butyldiphenylsilyl)oxy>methyl>-1,3-oxathiolan-5-yl>-N⁴-benzoylcytosine 
• 1321928-76-0 4-amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolane-5-yl)-1H-pyrimidin-2-one 2-fluorobenzoic acid salt 
• 1321928-75-9 5-(4-acetylamino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-[1,3]oxathiolane-2-carboxylic acid 2-isopropyl-5-methyl-cyclohexyl ester 
• 258832-61-0 2',3'-dideoxy-5-fluoro-3'-thiacytidine hydrochloride 
• 764659-72-5 (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (2R,5S)-5-(4-amino-5-fluoro-2-oxo-1,2-dihydro-1-pyrimidinyl)-1,3-oxathiolane-2-carboxylate 

Downstream Products

• 137530-41-7 racivir 
• 144371-00-6 (+)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 
• 144371-00-6 (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 
• 144371-00-6 (-)-(2S,5S)-5-fluoro-1-<2-(hydroxymethyl)-1,3-oxathiolan-5-yl>cytosine 
• 144371-00-6 (+)-(2R,5R)-5-fluoro-1-<2-(hydroxymethyl)-1,3-oxathiolan-5-yl>cytosine 
• 1365246-91-8 C₅₈H₇₂F₂N₆O₁₂S 
• 1365246-86-1 (-)-N₄-(4,4'-dimethoxytrityl)-5-fluoro-2',3'-dideoxy-3'-thiacytidine 
• 1365246-85-0 (-)-5'-O-(t-butyldimethylsilyl)-N₄-(4,4'-dimethoxytrityl)-5-fluoro-2',3'-dideoxy-3'-thiacytidine 
• 1365246-84-9 4-amino-1-((2R,5S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-1,3-oxathiolan-5-yl)-5-fluoropyrimidin-2(1H)-one 

Relevant articles and documents

Synthesis of (±)-Emtricitabine and (±)-Lamivudine by Chlorotrimethylsilane-Sodium Iodide-Promoted Vorbrüggen Glycosylation

By simple combination of water and sodium iodide (NaI) with chlorotrimethylsilane (TMSCl), promotion of a Vorbrüggen glycosylation en route to essential HIV drugs emtricitabine (FTC) and lamivudine (3TC) is achieved. TMSCl-NaI in wet solvent (0.1 M water)

Asymmetric preparation method for Emtricitabine

The invention provides an asymmetric preparation method for Emtricitabine. The preparation method comprises the steps of subjecting L-menthyl chloroformate, which serves as a raw material, to condensation with 2-halo ethanol, carrying out oxidation so as to obtain a stable intermediate, i.e., an aldehyde alcohol menthyl ester, subjecting the intermediate to condensation with 2,5-dihydroxyl-1,4-dithiane, carrying out halogenation, then, carrying out coupling with silanized 5-flucytosine, then, carrying out hydrolyzing, then, carrying out salt forming with salicylic acid, and finally, carrying out recrystallization, thereby obtaining purified Emtricitabine. According to the method, raw materials employed in a whole synthesis process are cheap and readily available, thus, the synthesis cost of the Emtricitabine disclosed by the invention is reduced greatly, the synthesis process is simple, the synthesis conditions are moderate, and the obtained Emtricitabine is relatively high in yield; and meanwhile, a chiral substrate is easy to remove during synthesis, produced pollutants, i.e., waste gases, waste water and waste residues are few, and thus, the method is applicable to industrial large-scale production of the Emtricitabine.

Asymmetric synthesis method of emtricitabine

The present invention provides an asymmetric synthesis method of emtricitabine. L-menthyl chloroformate is used as raw material to condense with 2-chloro-1-ethanol, then hydrolyze under the conditionof catalyst to obtain acetaldehyde alcohol optically active ester which is then induced by chiral promoter to condense with 2, 5-dihydroxyl-1,4-dithiane to give trans 5-hydroxyl-1,3-oxythiacyclopentane-2-methyl-L-menthol carbonate, the trans 5-hydroxyl-1,3-oxythiacyclopentane-2-methyl-L-menthol carbonate is halogenated and coupled with silanized 5-fluorocytosine, emtricitabine is obtained by removing the chiral auxiliary agent under the condition of weak alkalinity. As that raw materials used in the whole synthesis process are cheap and easy to obtain, the raw material utilization ratio is high, so that the synthesis cost of the emtricitabine is greatly reduced, and the synthesis process is simple, the synthesis condition is mild, the yield of the obtained emtricitabine is high, meanwhile,the chiral assistant is easy to remove in the synthesis process, the three waste pollutants generated are less, and the preparation method is suitable for the large-scale industrial production of theemtricitabine.